Neovascular Age-Related Macular Degeneration Treatment Market Report and Forecast 2024-2032

Neovascular Age-Related Macular Degeneration Treatment Market Report and Forecast 2024-2032


Neovascular Age-Related Macular Degeneration Treatment Market Outlook

The neovascular age-related macular degeneration treatment market was valued at USD 11 billion in 2023. The market size is anticipated to grow at a CAGR of 7.5% during the forecast period of 2024-2032 to achieve a value of USD 21.1 billion by 2032.

Neovascular Age-Related Macular Degeneration Treatment: Introduction

Neovascular Age-Related Macular Degeneration (nAMD) is a progressive eye condition that affects the macula, the central part of the retina responsible for sharp, central vision. It is a leading cause of severe vision loss and blindness among individuals over the age of 50. The condition is characterized by the growth of abnormal blood vessels beneath the macula, which can leak fluid and blood, leading to vision impairment. In a healthy eye, the macula receives a steady supply of oxygen and nutrients through a network of blood vessels. However, in nAMD, abnormal blood vessels start to grow beneath the macula. These new blood vessels are fragile and leak fluid and blood, leading to damage and scarring of the macula. This, in turn, causes distorted or blurry vision, difficulty recognizing faces or reading, and a loss of central vision.

Key Trends in Neovascular Age-Related Macular Degeneration Treatment Market

Key trends in the Neovascular Age-Related Macular Degeneration (nAMD) treatment market are:
  • Anti-vascular endothelial growth factor (anti-VEGF) therapies have been the mainstay of treatment for nAMD. Ongoing research and development efforts focus on improving the efficacy and durability of these therapies.
  • Researchers are exploring combination therapies to enhance the treatment outcomes in nAMD. These combinations may involve the use of anti-VEGF agents with other drugs, such as anti-inflammatory agents or angiogenesis inhibitors, to target multiple pathways involved in the development and progression of nAMD.
  • Gene therapies hold promise for the treatment of nAMD. These therapies involve the delivery of genetic material to the retinal cells to modulate the production of specific proteins involved in the disease process.
  • Researchers are investigating sustained drug delivery systems that can provide a continuous and controlled release of anti-VEGF drugs over an extended period. These systems can reduce the burden of frequent injections and improve patient compliance.
Neovascular Age-Related Macular Degeneration Treatment Market Segmentations

The market can be categorized into drug type, disease type, age group, disease stage, gender, distribution channel, and region.

Market Breakup by Drug Type
  • Ranibizumab
  • Aflibercept
  • Bevacizumab
  • Brolucizumab
  • Faricimab
  • Others
Market Breakup by Disease Type
  • Dry AMD
  • Wet AMD
Market Breakup by Age Group
  • Market Overview
  • Less Than 60
  • Between 60 to 80
  • More Than 80
Market Breakup by Disease Stage
  • Market Overview
  • Early-Stage AMD
  • Intermediate Stage AMD
  • Late-Stage AMD
Market Breakup by Gender
  • Male
  • Female
Market Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Market Breakup by Region -7MM
  • United States
  • EU-4 and the United Kingdom
Germany

France

Italy

Spain

United Kingdom
  • Japan
Neovascular Age-Related Macular Degeneration Treatment Market Overview

The nAMD treatment market has witnessed significant growth in recent years, driven by factors such as the increasing prevalence of nAMD, the aging population, and advancements in treatment options. The market is focused on providing effective therapies to slow down disease progression, improve visual outcomes, and enhance the quality of life for patients. There is a growing emphasis on early detection and diagnosis of nAMD to initiate timely treatment and improve visual outcomes. Regular eye examinations, coupled with advances in imaging technologies like optical coherence tomography (OCT) and fluorescein angiography (FA), contribute to early detection and monitoring of the disease.

Geographically, North America has been the largest market for nAMD treatment, primarily due to the high prevalence of the disease and well-established healthcare infrastructure. Europe has also shown significant market growth, driven by a growing elderly population. In the Asia-Pacific region, countries like China and India are witnessing increasing market growth due to improved healthcare facilities, rising awareness, and a growing patient population.

Key Players in the Neovascular Age-Related Macular Degeneration Treatment Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the neovascular age-related macular degeneration treatment market are as follows:
  • F. Hoffmann-La Roche Ltd
  • Bausch & Lomb
  • Novartis AG
  • Pfizer, Inc.
  • AbbVie Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Ophthotech Corporation
  • Alimera Sciences
  • GSK plc.
  • Bayer AG
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Macular Degeneration Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Macular Degeneration Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Neovascular Age-Related Macular Degeneration Treatment Epidemiology (2017-2032)
5.3 EU-4 and United Kingdom Neovascular Age-Related Macular Degeneration Treatment Epidemiology (2017-2032)
5.3.1 Germany Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032)
5.3.2 France Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032)
5.3.3 Italy Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032)
5.3.4 Spain Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032)
5.4 Japan Neovascular Age-Related Macular Degeneration Treatment Epidemiology (2017-2032)
6 Neovascular Age-Related Macular Degeneration Treatment Market Overview – 7MM
6.1 Neovascular Age-Related Macular Degeneration Treatment Market Historical Value (2017-2023)
6.2 Neovascular Age-Related Macular Degeneration Treatment Market Forecast Value (2024-2032)
7 Neovascular Age-Related Macular Degeneration Treatment Market Landscape – 7MM
7.1 Neovascular Age-Related Macular Degeneration Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Neovascular Age-Related Macular Degeneration Treatment: Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by Disease Type
7.2.3 Analysis by Age Group
7.2.4 Analysis by Disease Stage
7.2.5 Analysis by Gender
8 Neovascular Age-Related Macular Degeneration Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Neovascular Age-Related Macular Degeneration Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Neovascular Age-Related Macular Degeneration Treatment Market Segmentation – 7MM
11.1 Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
11.1.1 Market Overview
11.1.2 Ranibizumab
11.1.3 Aflibercept
11.1.4 Bevacizumab
11.1.5 Brolucizumab
11.1.6 Faricimab
11.1.7 Others
11.2 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
11.2.1 Market Overview
11.2.2 Dry AMD
11.2.3 Wet AMD
11.3 Neovascular Age-Related Macular Degeneration Treatment Market by Age Group
11.3.1 Market Overview
11.3.2 Less Than 60
11.3.3 Between 60 to 80
11.3.4 More Than 80
11.4 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Stage
11.4.1 Market Overview
11.4.2 Early-Stage AMD
11.4.3 Intermediate Stage AMD
11.4.4 Late-Stage AMD
11.5 Neovascular Age-Related Macular Degeneration Treatment Market by Gender
11.5.1 Market Overview
11.5.2 Male
11.5.3 Female
11.6 Neovascular Age-Related Macular Degeneration Treatment Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Retail Pharmacy
11.6.4 Online Pharmacy
11.7 Neovascular Age-Related Macular Degeneration Treatment Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.3.1 Germany
11.7.3.2 France
11.7.3.3 Italy
11.7.3.4 Spain
11.7.3.5 United Kingdom
11.7.4 Japan
12 United States Neovascular Age-Related Macular Degeneration Treatment Market
12.1 Neovascular Age-Related Macular Degeneration Treatment Market Historical Size (2017-2023)
12.2 Neovascular Age-Related Macular Degeneration Treatment Market Forecast Size (2024-2032)
12.3 Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
12.4 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
13 EU-4 and United Kingdom Neovascular Age-Related Macular Degeneration Treatment Market
13.1 Neovascular Age-Related Macular Degeneration Treatment Market Historical Value (2017-2023)
13.2 Neovascular Age-Related Macular Degeneration Treatment Market Forecast Value (2024-2032)
13.3 Germany Neovascular Age-Related Macular Degeneration Treatment Market Overview
13.3.1 Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
13.3.2 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
13.4 France Neovascular Age-Related Macular Degeneration Treatment Market Overview
13.4.1 Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
13.4.2 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
13.5 Italy Neovascular Age-Related Macular Degeneration Treatment Market Overview
13.5.1 Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
13.5.2 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
13.6 Spain Neovascular Age-Related Macular Degeneration Treatment Market Overview
13.6.1 Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
13.6.2 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
13.7 United Kingdom Neovascular Age-Related Macular Degeneration Treatment Market Overview
13.7.1 Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
13.7.2 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
14 Japan Neovascular Age-Related Macular Degeneration Treatment Market
14.1 Neovascular Age-Related Macular Degeneration Treatment Market Historical Value (2017-2023)
14.2 Neovascular Age-Related Macular Degeneration Treatment Market Forecast Value (2024-2032)
14.3 Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
14.4 Neovascular Age-Related Macular Degeneration Treatment Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by Year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 F. Hoffmann-La Roche Ltd
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Company News
21.1.5 Certifications
21.2 Bausch & Lomb
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Company News
21.2.5 Certifications
21.3 Novartis AG
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Company News
21.3.5 Certifications
21.4 Pfizer, Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Company News
21.4.5 Certifications
21.5 AbbVie Inc.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Company News
21.5.5 Certifications
21.6 Santen Pharmaceutical Co., Ltd.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Company News
21.6.5 Certifications
21.7 Ophthotech Corporation
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Company News
21.7.5 Certifications
21.8 Alimera Sciences
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Company News
21.8.5 Certifications
21.9 GSK plc.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Company News
21.9.5 Certifications
21.10 Bayer AG
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Company News
21.10.5 Certifications
22 Neovascular Age-Related Macular Degeneration Treatment - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings